Compare REVG & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REVG | ITRM |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | Ireland |
| Employees | 5700 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 24.3M |
| IPO Year | 2017 | 2018 |
| Metric | REVG | ITRM |
|---|---|---|
| Price | $60.74 | $0.36 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $48.00 | $9.00 |
| AVG Volume (30 Days) | 644.0K | ★ 703.3K |
| Earning Date | 12-10-2025 | 02-06-2026 |
| Dividend Yield | ★ 0.39% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.89 | N/A |
| Revenue | ★ $2,463,500,000.00 | $390,000.00 |
| Revenue This Year | $9.52 | N/A |
| Revenue Next Year | $7.89 | $193.01 |
| P/E Ratio | $32.35 | ★ N/A |
| Revenue Growth | ★ 3.50 | N/A |
| 52 Week Low | $26.51 | $0.28 |
| 52 Week High | $64.47 | $2.10 |
| Indicator | REVG | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 59.73 | 39.51 |
| Support Level | $60.99 | $0.28 |
| Resistance Level | $62.67 | $0.37 |
| Average True Range (ATR) | 1.17 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 57.43 | 37.65 |
REV Group Inc is a U.S.-based designer, manufacturer, and distributor of specialty vehicles and related aftermarket parts and services, operating through two segments: Specialty Vehicles and Recreational Vehicles. The Specialty Vehicles segment includes fire apparatus, ambulances, terminal trucks, and sweepers sold under brands such as E-One, Ferrara, KME, Spartan ER, AEV, Horton, Leader, Road Rescue, Wheeled Coach, Capacity, and LayMor. The Recreational Vehicles segment includes American Coach, Fleetwood RV, Holiday Rambler, Renegade RV, and Midwest Automotive Designs, offering Class A, B, C, and Super C motorized RVs and products from Goldshield Fiberglass. The majority of revenue is generated from the Specialty Vehicles segment.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.